July 15th 2025
The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
CVS Cuts Out In-House Dispensaries of Cancer Drugs
October 20th 2016A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.
Read More
What's Next for Immunotherapy in GBM: IDO Inhibitors, Vaccines, and PD-L1 Antibody Combinations
October 18th 2016Rimas Lukas, MD, discusses the next steps in glioblastoma research, as well as the potential use of IDO inhibitors in the treatment of GBM, and recent studies showing promise in the field.
Read More
Tumor-Treating Fields Make Significant Impact in GBM and Beyond
October 18th 2016Optune, a noninvasive device that delivers tumor-treating fields to the brain, provides oncologists, specifically those who treat glioblastoma multiforme, an opportunity to apply technology as part of their standard treatment regimen.
Read More
Computer Simulation Helps Plan Transducer Placement in Glioblastoma
October 14th 2016For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.
Read More
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
October 9th 2016Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Watch
Researchers Join Forces to Accelerate Progress in Pediatric High-Grade Gliomas
September 20th 2016Goals of "Project Impact: A Campaign to Defeat Pediatric Brain Tumors" include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.
Read More
NCCN Issues Updated Recommendation for Optune as a Treatment for GBM
August 22nd 2016The National Comprehensive Cancer Network has issued an updated recommendation for Optune for use in combination with temozolomide as standard treatment for patients with newly diagnosed glibolastoma multiforme.
Read More
An Overview of the MA17R Trial in Breast Cancer
July 29th 2016Frankie Ann Holmes, MD, medical oncologist, Texas Oncology, discusses the implications of the results of the MA17R trial, which is a randomized phase III clinical trial that examined the benefits of extending aromatase inhibitors with letrozole as a treatment for postmenopausal patients with early breast cancer.
Watch
The Challenges in Using Immune Checkpoint Inhibitors to Treat Patients With Glioblastoma
July 14th 2016David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the important considerations and challenges in using immune checkpoint inhibitors to treat patients with glioblastoma.
Watch
Temozolomide Plus Radiotherapy Boosts Overall Survival for Elderly Patients with Glioblastoma
July 13th 2016Adding temozolomide to short-course radiotherapy after surgery in elderly patients with glioblastoma boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8%.
Read More
Tandem Transplant in Neuroblastoma Leads to Significant Survival Advantage
June 18th 2016Dual autologous stem-cell transplant (ASCT) led to a 13% absolute increase in 3-year event-free survival (EFS) for children with high-risk neuroblastoma as compared with a single transplant, a large randomized trial showed.
Read More
Two Immunotherapy Combinations Show Promise in Glioblastoma
June 15th 2016The combinations of nivolumab (Opdivo) plus ipilimumab (Yervoy) and pembrolizumab (Keytruda) plus bevacizumab (Avastin ), both show promising efficacy in recent trials, possibly paving the way toward a new era of treatment for patients with glioblastoma.
Read More
Nivolumab Monotherapy Shows Encouraging Efficacy in Glioblastoma Patients
June 11th 2016Patients with recurrent glioblastoma mutliforme reacted well to nivolumab (Opdivo) monotherapy, according to findings from the CheckMate-143 trial that were presented at the 2016 ASCO Annual Meeting. The single agent showed a manageable safety profile and promising efficacy signs during the course of the study.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More